• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Retinoblastoma - Pipeline Review, H2 2011 - Product Image

Retinoblastoma - Pipeline Review, H2 2011

  • Published: October 2011
  • 57 pages
  • Global Markets Direct

Retinoblastoma - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Retinoblastoma - Pipeline Review, H2 2011', provides an overview of the Retinoblastoma therapeutic pipeline. This report provides information on the therapeutic development for Retinoblastoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinoblastoma. 'Retinoblastoma - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Retinoblastoma.
- A review of the Retinoblastoma products under development by companies and universities/research institutes based on information READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Retinoblastoma Overview
Therapeutics Development
An Overview of Pipeline Products for Retinoblastoma
Retinoblastoma Therapeutics under Development by Companies
Retinoblastoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Retinoblastoma Therapeutics - Products under Development by Companies
Retinoblastoma Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Retinoblastoma Therapeutics Development
RXi Pharmaceuticals Corporation
Neotropix, Inc.
Retinoblastoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
NTX-010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amifostine Trihydrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Becatecarin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Torisel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Melphalan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Carboplatin + Cyclosporine + Etoposide + Vincristine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Topotecan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vincristine + Carboplatin + Topotecan + Etoposide + Filgrastim + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vincristine + Carboplatin + Filgrastim + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Carboplatin + Etoposide + Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Etoposide + Vincristine + Filgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vincristine + Cyclophosphamide + Doxorubicin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Vincristine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMC-A12 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Retinal Disorder Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vincristine + Cyclophosphamide + Doxorubicin + Carboplatin + Etoposide + Filgrastim + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Melphalan Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Retinoblastoma Therapeutics – Drug Profile Updates
Retinoblastoma Therapeutics - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos